Hagop Kantarjian, MD: Inotuzumab Ozogamicin for Relapsed/Refractory Ph-Positive Acute Lymphoblastic Leukemia

Among patients with relapsed/refractory acute lymphoblastic leukemia (ALL), those with Philadelphia chromosome (Ph)-positive disease experience a higher rate of relapse and poorer chances of long-term survival. According to results of the phase 3 INO-VATE trial recently published in Cancer, inotuzumab ozogamicin, a humanized anti-CD22 monoclonal antibody, achieved high rates of response, remission, and progression-free survival in patients with this disease. In this interview with i3 Health, Hag...
Continue reading

Vitamin D Supplements for Reducing Advanced Cancer Risk: Paulette Chandler, MD, MPH

In a study recently published in JAMA Network Open, a team of investigators led by Paulette Chandler, MD, MPH, found that vitamin D supplementation is associated with a decreased risk of developing advanced cancer, particularly among individuals with a normal body mass index (BMI). In this interview with i3 Health, Dr. Chandler, an Assistant Professor of Medicine at Harvard Medical School, discusses the significance of these results and the ongoing research investigating vitamin D supplementatio...
Continue reading

Atezolizumab for Previously Treated Non-Small Cell Lung Cancer: Julien Mazières, MD, PhD

For patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC), effective treatment options with minimal toxicity remain limited. In this interview with i3 Health, Julien Mazières, MD, PhD, Professor of Respiratory Medicine at Toulouse University Hospital, discusses his collaborative research finding that atezolizumab increases long-term overall survival compared with docetaxel, regardless of histology, subsequent immunotherapy, and programmed death ligand...
Continue reading

Paul Sargos, MD on Adjuvant RT versus Salvage RT for Prostate Cancer

Results of a new study presented at American Society of Radiation Oncology (ASTRO) 2020 reveal that adjuvant radiotherapy (aRT) significantly increased the risk of late toxicity compared with salvage radiotherapy (sRT). Lead author of the study, Paul Sargos, MD, discusses the significance of these results in addition to advice for community oncologists treating this patient population in this interview with i3 Health. What was the rationale for this study? Paul Sargos, MD: To understand the impo...
Continue reading

Nivolumab/Ipilimumab for Malignant Pleural Mesothelioma: Paul Baas, MD, PhD

The FDA recently approved nivolumab/ipilimumab for the first-line treatment of malignant pleural mesothelioma, marking the second FDA approval for this condition and the first approval in the past 16 years. In this interview, Paul Baas, MD, PhD, principal investigator of the CheckMate 743 trial (NCT02899299), on which the approval was based, speaks with Oncology Data Advisor about the benefits and tolerability of nivolumab/ipilimumab, ongoing research advances in the treatment of malignant pleur...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.